EBAMED SA

Their core work

EBAMED SA is a Swiss medical device startup developing Cardio-kit, a device designed to make proton therapy a viable, non-invasive treatment for cardiac arrhythmias — a condition currently addressed mainly through ablation or lifelong medication. Their core technical contribution is real-time heart motion tracking combined with machine learning to steer a proton beam automatically, compensating for cardiac movement during treatment. They progressed from feasibility validation (SME-1, 2019) to a full development project (SME-2, 2020–2023), indicating a mature product development trajectory. Their work sits at the intersection of radiation oncology hardware, cardiology, and embedded AI — a technically demanding niche with few competitors.

What they specialise in

How they've shifted over time

EBAMED's H2020 portfolio spans only 2019–2020, so there is no meaningful long-term evolution to trace — both projects are phases of a single product development. The SME-1 project (2019) carried no keywords, consistent with a pre-competitive feasibility study; all technical depth (proton therapy, machine learning, heart motion tracking) emerged in the SME-2 phase (2020). This reflects a startup maturing from concept to prototype rather than a shift in research direction. Their focus has remained tightly singular throughout.

EBAMED is moving from feasibility into full product development, suggesting they are approaching clinical validation or commercialization of Cardio-kit — making them a candidate for partnerships with hospitals, radiation oncology centers, or MedTech commercialization networks.

How they like to work

EBAMED operates exclusively as a solo coordinator through the SME Instrument (now EIC Accelerator), which by design funds individual companies without consortium requirements — so their zero-partner record reflects the funding instrument, not a preference for isolation. They have not appeared as a partner in other organizations' projects, suggesting they are a focused product company rather than a collaborative research group. Anyone engaging them should expect a company-led, product-driven dynamic rather than an academic consortium model.

EBAMED has no recorded consortium partners across their H2020 projects, which is expected given the solo-applicant nature of the SME Instrument. Their collaboration network within the EU research system is effectively unknown from this data alone.

What sets them apart

EBAMED occupies a rare technical niche: applying proton therapy — a modality dominated by oncology — to cardiac arrhythmia treatment, a use case that almost no other European company is pursuing at this scale. Their combination of real-time motion compensation and machine learning for beam control is a specific engineering challenge that bridges radiation physics, cardiology, and embedded AI. For a consortium needing deep domain expertise in radiation-based cardiac devices or motion-adaptive treatment delivery, they have no obvious European equivalent among H2020 SMEs.

Highlights from their portfolio

• Cardio-kit (SME-2)
  At €2.4M, this is one of the larger EIC SME Instrument Phase 2 grants and represents a full product development commitment to an entirely new clinical application of proton therapy.
• Cardio-kit (SME-1)
  The SME-1 feasibility grant confirms the concept passed independent expert evaluation before the larger Phase 2 award — validating the technical premise of the approach.